SAN FRANCISCO – Roll-in patients with symptomatic mitral regurgitation (MR) or severe mitral annular calcification (MAC) who undergo transcatheter mitral valve replacement (TMVR) via the Tendyne System showed 100% procedural survival and maintained MR elimination through 1 year, as well as improved quality of life and heart failure symptoms, according to an early look at the SUMMIT Tendyne trial.